Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Options
Discovery Communications put volume heavy and directionally bearish » 15:55
06/16/21
06/16
15:55
06/16/21
15:55
DISCK

Discovery Inc.

$28.68 /

+0.37 (+1.31%)

Bearish flow noted in…

Bearish flow noted in Discovery Communications with 2,238 puts trading, or 1.9x expected. Most active are Jul-21 27.5 puts and Jul-21 32.5 calls, with total volume in those strikes near 2,000 contracts. The Put/Call Ratio is 2.21, while ATM IV is up over 3 points on the day. Earnings are expected on August 4th.

ShowHide Related Items >><<
DISCK Discovery Inc.
$28.68 /

+0.37 (+1.31%)

DISCK Discovery Inc.
$28.68 /

+0.37 (+1.31%)

05/24/21 Morgan Stanley
AT&T price target lowered to $32 from $34 at Morgan Stanley
05/24/21 MoffettNathanson
MoffettNathanson downgrades Discovery to Neutral after WarnerMedia deal news
05/24/21 MoffettNathanson
Discovery downgraded to Neutral from Buy at MoffettNathanson
05/17/21 JPMorgan
JPMorgan suspends rating for AT&T after WarnerMedia, Discovery deal announcement
  • 14
    Apr
  • 24
    Feb
DISCK Discovery Inc.
$28.68 /

+0.37 (+1.31%)

DISCK Discovery Inc.
$28.68 /

+0.37 (+1.31%)

DISCK Discovery Inc.
$28.68 /

+0.37 (+1.31%)

Upgrade
AT&T upgraded to Sector Perform from Underperform at Scotiabank » 15:24
06/16/21
06/16
15:24
06/16/21
15:24
T

AT&T

$29.10 /

-0.19 (-0.65%)

Scotiabank analyst…

Scotiabank analyst Jeffrey Fan upgraded AT&T to Sector Perform from Underperform with a price target of $31, up from $28.

ShowHide Related Items >><<
T AT&T
$29.10 /

-0.19 (-0.65%)

T AT&T
$29.10 /

-0.19 (-0.65%)

06/16/21 Pivotal Research
Dish upgraded to Buy from Hold at Pivotal Research
05/24/21 Morgan Stanley
AT&T price target lowered to $32 from $34 at Morgan Stanley
05/24/21 Benchmark
Benchmark does not 'attach any credence' to idea AT&T could buy Charter
05/24/21 MoffettNathanson
MoffettNathanson downgrades Discovery to Neutral after WarnerMedia deal news
T AT&T
$29.10 /

-0.19 (-0.65%)

T AT&T
$29.10 /

-0.19 (-0.65%)

T AT&T
$29.10 /

-0.19 (-0.65%)

T AT&T
$29.10 /

-0.19 (-0.65%)

Recommendations
Altimmune price target raised to $53 from $45 at JMP Securities » 12:38
06/16/21
06/16
12:38
06/16/21
12:38
ALT

Altimmune

$17.19 /

+3.03 (+21.40%)

JMP Securities analyst…

JMP Securities analyst Jonathan Wolleben raised the firm's price target on Altimmune to $53 from $45 and keeps an Outperform rating on the shares, noting that the 6% placebo-adjusted body weight reduction seen in early Phase 1 data for ALT-801 doubled his expectation. Based on the data, he has raised his view on the odds of success for ALT-801 in obesity to 40% from 30%, noted Wolleben.

ShowHide Related Items >><<
ALT Altimmune
$17.19 /

+3.03 (+21.40%)

ALT Altimmune
$17.19 /

+3.03 (+21.40%)

06/16/21 H.C. Wainwright
H.C. Wainwright says Altimmune has 'potential blockbuster indication' in obesity
06/16/21 Piper Sandler
Altimmune weight loss data 'outstanding,' says Piper Sandler
06/02/21 H.C. Wainwright
Altimmune initiated with a Buy at H.C. Wainwright
05/17/21 Piper Sandler
Street should 'pay attention' to Altimmune in June, says Piper Sandler
ALT Altimmune
$17.19 /

+3.03 (+21.40%)

  • 14
    Jul
ALT Altimmune
$17.19 /

+3.03 (+21.40%)

ALT Altimmune
$17.19 /

+3.03 (+21.40%)

Recommendations
H.C. Wainwright says Altimmune has 'potential blockbuster indication' in obesity » 11:00
06/16/21
06/16
11:00
06/16/21
11:00
ALT

Altimmune

$15.90 /

+1.74 (+12.29%)

After Altimmune announced…

After Altimmune announced "positive" interim data on ALT-801 in a Phase 1 trial in overweight and obese volunteers, H.C. Wainwright analyst Patrick Trucchio noted that Altimmune remains on track to report top-line data following 12 weeks of dosing in Q3 and that it intends to file a second Investigational New Drug application in obesity to supplement its ongoing non-alcoholic steatohepatitis, or NASH, program. The analyst, who sees obesity as "a second potential blockbuster indication" for ALT-801, reiterates a Buy rating on Altimmune with a $35 price target.

ShowHide Related Items >><<
ALT Altimmune
$15.90 /

+1.74 (+12.29%)

ALT Altimmune
$15.90 /

+1.74 (+12.29%)

06/16/21 Piper Sandler
Altimmune weight loss data 'outstanding,' says Piper Sandler
06/02/21 H.C. Wainwright
Altimmune initiated with a Buy at H.C. Wainwright
05/17/21 Piper Sandler
Street should 'pay attention' to Altimmune in June, says Piper Sandler
03/26/21 Piper Sandler
AstraZeneca plan 'opens the door' for Altimmune interest, says Piper Sandler
ALT Altimmune
$15.90 /

+1.74 (+12.29%)

  • 14
    Jul
ALT Altimmune
$15.90 /

+1.74 (+12.29%)

ALT Altimmune
$15.90 /

+1.74 (+12.29%)

On The Fly
Coinbase initiation, Dish upgrade among today's top calls on Wall Street » 09:54
06/16/21
06/16
09:54
06/16/21
09:54
COIN

Coinbase

$232.82 /

+0.86 (+0.37%)

, DISH

Dish

$41.68 /

+1.52 (+3.78%)

, T

AT&T

$29.28 /

-0.01 (-0.03%)

, AFRM

Affirm

$68.92 /

+1.685 (+2.51%)

, SQSP

Squarespace

$59.58 /

+1.77 (+3.06%)

, NCLH

Norwegian Cruise Line

$31.43 /

+0.58 (+1.88%)

, CCL

Carnival

$29.21 /

+0.595 (+2.08%)

, RCL

Royal Caribbean

$88.16 /

+1.28 (+1.47%)

Check out today's top…

ShowHide Related Items >><<
T AT&T
$29.28 /

-0.01 (-0.03%)

SQSP Squarespace
$59.58 /

+1.77 (+3.06%)

RCL Royal Caribbean
$88.16 /

+1.28 (+1.47%)

NCLH Norwegian Cruise Line
$31.43 /

+0.58 (+1.88%)

DISH Dish
$41.68 /

+1.52 (+3.78%)

COIN Coinbase
$232.82 /

+0.86 (+0.37%)

CCL Carnival
$29.21 /

+0.595 (+2.08%)

AFRM Affirm
$68.92 /

+1.685 (+2.51%)

COIN Coinbase
$232.82 /

+0.86 (+0.37%)

06/16/21
Fly Intel: Top five analyst initiations
06/16/21 Canaccord
Coinbase initiated with a Buy at Canaccord
06/16/21 Canaccord
Coinbase initiated with a Buy at Canaccord
06/08/21 Raymond James
Raymond James starts Coinbase at Underperform, sees fee compression coming
DISH Dish
$41.68 /

+1.52 (+3.78%)

06/16/21
Fly Intel: Top five analyst upgrades
06/16/21 Pivotal Research
Dish upgraded to Buy from Hold at Pivotal Research
06/09/21
Fly Intel: Top five analyst downgrades
06/09/21 JPMorgan
JPMorgan downgrades Dish to sell on wireless execution concerns
T AT&T
$29.28 /

-0.01 (-0.03%)

05/24/21 Morgan Stanley
AT&T price target lowered to $32 from $34 at Morgan Stanley
05/24/21 Benchmark
Benchmark does not 'attach any credence' to idea AT&T could buy Charter
05/24/21 MoffettNathanson
MoffettNathanson downgrades Discovery to Neutral after WarnerMedia deal news
AFRM Affirm
$68.92 /

+1.685 (+2.51%)

06/15/21 Mizuho
Affirm initiated with a Buy at Mizuho
06/15/21 Lake Street
Spring Valley Acquisition Corp. initiated with a Buy at Lake Street
06/02/21 Truist
Affirm price target raised to $82 from $77 at Truist
06/01/21 BofA
Affirm upgraded to Buy from Neutral at BofA
SQSP Squarespace
$59.58 /

+1.77 (+3.06%)

06/15/21 Mizuho
Squarespace initiated with a Buy at Mizuho
06/14/21
Fly Intel: Top five analyst initiations
06/14/21 Raymond James
Raymond James starts Squarespace at Outperform, sees 15%-20% growth
06/14/21 JPMorgan
Squarespace initiated with an Overweight at JPMorgan
NCLH Norwegian Cruise Line
$31.43 /

+0.58 (+1.88%)

06/16/21 Wolfe Research
Wolfe upgrades 'Big 3' cruise stocks on improving booking momentum
06/16/21 Wolfe Research
Norwegian Cruise upgraded to Outperform from Peer Perform at Wolfe Research
06/11/21 Credit Suisse
Royal Caribbean selloff on Covid cases an opportunity, says Credit Suisse
06/09/21 Stifel
Norwegian Cruise Line price target raised to $40 from $37 at Stifel
CCL Carnival
$29.21 /

+0.595 (+2.08%)

06/16/21 Wolfe Research
Carnival upgraded to Outperform from Peer Perform at Wolfe Research
06/11/21 Argus
Carnival price target raised to $35 from $33 at Argus
RCL Royal Caribbean
$88.16 /

+1.28 (+1.47%)

06/16/21 Wolfe Research
Royal Caribbean upgraded to Outperform from Peer Perform at Wolfe Research
04/29/21 William Blair
Royal Caribbean March bookings on par with 2019 peak wave, says William Blair
T AT&T
$29.28 /

-0.01 (-0.03%)

RCL Royal Caribbean
$88.16 /

+1.28 (+1.47%)

NCLH Norwegian Cruise Line
$31.43 /

+0.58 (+1.88%)

DISH Dish
$41.68 /

+1.52 (+3.78%)

COIN Coinbase
$232.82 /

+0.86 (+0.37%)

CCL Carnival
$29.21 /

+0.595 (+2.08%)

AFRM Affirm
$68.92 /

+1.685 (+2.51%)

  • 19
    May
  • 14
    Apr
  • 05
    Mar
  • 01
    Mar
  • 23
    Feb
  • 13
    Jan
  • 18
    Nov
  • 14
    Oct
  • 17
    Jul
T AT&T
$29.28 /

-0.01 (-0.03%)

RCL Royal Caribbean
$88.16 /

+1.28 (+1.47%)

NCLH Norwegian Cruise Line
$31.43 /

+0.58 (+1.88%)

DISH Dish
$41.68 /

+1.52 (+3.78%)

COIN Coinbase
$232.82 /

+0.86 (+0.37%)

AFRM Affirm
$68.92 /

+1.685 (+2.51%)

T AT&T
$29.28 /

-0.01 (-0.03%)

SQSP Squarespace
$59.58 /

+1.77 (+3.06%)

RCL Royal Caribbean
$88.16 /

+1.28 (+1.47%)

NCLH Norwegian Cruise Line
$31.43 /

+0.58 (+1.88%)

DISH Dish
$41.68 /

+1.52 (+3.78%)

COIN Coinbase
$232.82 /

+0.86 (+0.37%)

CCL Carnival
$29.21 /

+0.595 (+2.08%)

AFRM Affirm
$68.92 /

+1.685 (+2.51%)

T AT&T
$29.28 /

-0.01 (-0.03%)

SQSP Squarespace
$59.58 /

+1.77 (+3.06%)

RCL Royal Caribbean
$88.16 /

+1.28 (+1.47%)

NCLH Norwegian Cruise Line
$31.43 /

+0.58 (+1.88%)

DISH Dish
$41.68 /

+1.52 (+3.78%)

COIN Coinbase
$232.82 /

+0.86 (+0.37%)

CCL Carnival
$29.21 /

+0.595 (+2.08%)

AFRM Affirm
$68.92 /

+1.685 (+2.51%)

Recommendations
Altimmune weight loss data 'outstanding,' says Piper Sandler » 08:31
06/16/21
06/16
08:31
06/16/21
08:31
ALT

Altimmune

$14.16 /

-0.1 (-0.70%)

Piper Sandler analyst…

Piper Sandler analyst Yasmeen Rahimi says Altimmune this morning reported "outstanding" topline data from its 6-week Phase 1b study testing two doses of ALT-801 "showing best in-class activity" in weight loss with transient nausea and no rates of vomiting, diarrhea, constipation. The analyst found it outstanding to see a 5.4% weight reduction at 1.8 mg and a 1.8% reduction at 1.2 mg, compared to a 0.9% increase in weight for the placebo group. Rahimi keeps an Overweight rating on Altimmune with an $80 price target. The stock in premarket trading is up 4% to $14.72.

ShowHide Related Items >><<
ALT Altimmune
$14.16 /

-0.1 (-0.70%)

ALT Altimmune
$14.16 /

-0.1 (-0.70%)

06/02/21 H.C. Wainwright
Altimmune initiated with a Buy at H.C. Wainwright
05/17/21 Piper Sandler
Street should 'pay attention' to Altimmune in June, says Piper Sandler
03/26/21 Piper Sandler
AstraZeneca plan 'opens the door' for Altimmune interest, says Piper Sandler
02/18/21 B. Riley
Altimmune price target raised to $41 from $28 at B. Riley Securities
ALT Altimmune
$14.16 /

-0.1 (-0.70%)

  • 14
    Jul
ALT Altimmune
$14.16 /

-0.1 (-0.70%)

ALT Altimmune
$14.16 /

-0.1 (-0.70%)

Hot Stocks
AppHarvest complete deal with Rabo AgriFinance to secure $75M to fuel expansion » 07:32
06/16/21
06/16
07:32
06/16/21
07:32
APPH

AppHarvest

$15.54 /

-0.89 (-5.42%)

AppHarvest announced it…

AppHarvest announced it has completed a deal with Rabo AgriFinance, a subsidiary of Rabobank, to secure $75M to fuel expansion of its rapidly growing network of high-tech controlled environment agriculture facilities in Central Appalachia. Under the credit facility, AppHarvest has entered into a 60% loan-to-value mortgage at an anticipated fixed rate of between 4%-5% for 10 years with amortization of debt over 20 years for its flagship farm in Morehead, Kentucky, which began its first shipments of produce in January of this year. The first farm is expected to be capable of producing more than 40M pounds of tomatoes annually and currently is serving some of the top national grocery store chains and food service outlets such as Kroger and Wendy's. AppHarvest has announced that its development plan calls for a network of 12 high-tech farms by the end of 2025. The company expects to expand production next year to include leafy greens and strawberries.

ShowHide Related Items >><<
APPH AppHarvest
$15.54 /

-0.89 (-5.42%)

APPH AppHarvest
$15.54 /

-0.89 (-5.42%)

06/16/21 Barclays
AppHarvest initiated with an Overweight at Barclays
02/11/21
Fly Intel: Top five analyst initiations
02/11/21 Cowen
AppHarvest appealing to food and water investors, Cowen starts with Outperform
02/11/21 Cowen
AppHarvest initiated with an Outperform at Cowen
APPH AppHarvest
$15.54 /

-0.89 (-5.42%)

APPH AppHarvest
$15.54 /

-0.89 (-5.42%)

APPH AppHarvest
$15.54 /

-0.89 (-5.42%)

Hot Stocks
Altimmune announces interim data from ALT-801 phase 1 trial » 07:10
06/16/21
06/16
07:10
06/16/21
07:10
ALT

Altimmune

$14.16 /

-0.1 (-0.70%)

Altimmune announced…

Altimmune announced results from a prespecified 6-week interim analysis of its ongoing 12-week, Phase 1, placebo-controlled, single and multiple ascending dose trial of ALT-801, an investigational GLP-1/glucagon dual receptor agonist, in healthy overweight and obese volunteers. The study is currently being conducted in Australia under a clinical trial application. The interim data showed a mean weight loss of 5.4% was achieved by Week 6 with a once weekly ALT-801 dose of 1.8 mg administered subcutaneously, sc, compared to a weight gain of 0.9% in the placebo group, surpassing the pre-established treatment target of 2% weight loss. All but one subject who received the 1.8 mg sc dose achieved at least 3% weight loss by Week 6. A lower dose cohort that received a weekly 1.2 mg sc dose achieved a mean weight loss of 1.8% at the same time point. ALT-801 was well-tolerated without dose titration, with transient nausea rates of 14.3% at the 1.2 mg dose and 22.2% at the 1.8 mg dose, and no reports of vomiting, diarrhea or constipation at either dose. All nausea events at the 1.8 mg dose were mild in severity. Because the recruited study population was young and non-diabetic, the proportion of subjects with MRI-PDFF greater than 10% was insufficient to perform an analysis of liver fat reduction in this population. Consequently, the company plans to expand the enrollment criteria and conduct a separate 12-week Phase 1b study of diabetic and non-diabetic subjects with non-alcoholic fatty liver disease in the United States, which is anticipated to commence in Q3 2021, and to initiate a 52-week biopsy-driven NASH trial in Q1 2022. The ALT-801 Phase 1 trial is currently progressing through higher dose cohorts, and the company plans to report the results following 12-weeks of dosing in Q3 2021. Based on these latest results, Altimmune now plans to file a second IND in obesity in Q3 2021 to supplement its ongoing NASH program.

ShowHide Related Items >><<
ALT Altimmune
$14.16 /

-0.1 (-0.70%)

ALT Altimmune
$14.16 /

-0.1 (-0.70%)

06/02/21 H.C. Wainwright
Altimmune initiated with a Buy at H.C. Wainwright
05/17/21 Piper Sandler
Street should 'pay attention' to Altimmune in June, says Piper Sandler
03/26/21 Piper Sandler
AstraZeneca plan 'opens the door' for Altimmune interest, says Piper Sandler
02/18/21 B. Riley
Altimmune price target raised to $41 from $28 at B. Riley Securities
ALT Altimmune
$14.16 /

-0.1 (-0.70%)

  • 14
    Jul
ALT Altimmune
$14.16 /

-0.1 (-0.70%)

ALT Altimmune
$14.16 /

-0.1 (-0.70%)

Initiation
AppHarvest initiated with an Overweight at Barclays » 05:54
06/16/21
06/16
05:54
06/16/21
05:54
APPH

AppHarvest

$15.54 /

-0.89 (-5.42%)

Barclays analyst Benjamin…

Barclays analyst Benjamin Theurer initiated coverage of AppHarvest with an Overweight rating and $25 price target. AppHarvest via its special purpose acquisition company deal, raised sufficient capital to pursue its first three years of expansion, Theurer tells investors in a research note. The analyst models four year annual revenue growth of 103% and finds the shares attractively valued. There's "plenty of space available to meet the need to build high-tech greenhouses," says Theurer.

ShowHide Related Items >><<
APPH AppHarvest
$15.54 /

-0.89 (-5.42%)

APPH AppHarvest
$15.54 /

-0.89 (-5.42%)

02/11/21
Fly Intel: Top five analyst initiations
02/11/21 Cowen
AppHarvest appealing to food and water investors, Cowen starts with Outperform
02/11/21 Cowen
AppHarvest initiated with an Outperform at Cowen
APPH AppHarvest
$15.54 /

-0.89 (-5.42%)

APPH AppHarvest
$15.54 /

-0.89 (-5.42%)

APPH AppHarvest
$15.54 /

-0.89 (-5.42%)

Conference/Events
European Hematology Association to hold virtual meeting » 04:55
06/16/21
06/16
04:55
06/16/21
04:55
APTO

Aptose Biosciences

$3.50 /

-0.21 (-5.66%)

, MBIO

Mustang Bio

$3.57 /

-0.115 (-3.13%)

, QURE

uniQure

$34.46 /

-0.43 (-1.23%)

, RIGL

Rigel Pharmaceuticals

$4.27 /

-0.1 (-2.29%)

, MGTA

Magenta Therapeutics

$11.38 /

+0.05 (+0.44%)

, MEIP

MEI Pharma

$3.10 /

-0.15 (-4.62%)

, CRIS

Curis

$7.61 /

-0.44 (-5.47%)

, XLRN

Acceleron

$128.63 /

-2.39 (-1.82%)

, EPZM

Epizyme

$8.79 /

-0.025 (-0.28%)

, INCY

Incyte

$82.69 /

+0.11 (+0.13%)

, ORTX

Orchard Therapeutics

$4.85 /

-0.19 (-3.77%)

, TGTX

TG Therapeutics

$37.42 /

-0.88 (-2.30%)

, EQ

Equillium

$6.05 /

+0.05 (+0.83%)

, JAZZ

Jazz Pharmaceuticals

$183.42 /

-2.7 (-1.45%)

, VRTX

Vertex Pharmaceuticals

$188.94 /

-5.87 (-3.01%)

, SGEN

Seagen

$153.20 /

-2.99 (-1.91%)

, IMRA

Imara

$8.26 /

-0.44 (-5.06%)

, GBT

Global Blood Therapeutics

$39.60 /

-0.65 (-1.61%)

, BGNE

BeiGene

$332.97 /

-9.75 (-2.84%)

, APLS

Apellis

$60.63 /

-4.27 (-6.58%)

, AGIO

Agios Pharmaceuticals

$58.23 /

+0.04 (+0.07%)

, FMTX

Forma Therapeutics

$24.13 /

-0.09 (-0.37%)

, KROS

Keros Therapeutics

$52.55 /

-0.455 (-0.86%)

, CYAD

Celyad

$5.44 /

+0.03 (+0.55%)

, ALXN

Alexion

$181.90 /

+0.25 (+0.14%)

EHA 2021 Virtual Congress…

EHA 2021 Virtual Congress to be held on June 9-17. Webcast Link

ShowHide Related Items >><<
XLRN Acceleron
$128.63 /

-2.39 (-1.82%)

VRTX Vertex Pharmaceuticals
$188.94 /

-5.87 (-3.01%)

TGTX TG Therapeutics
$37.42 /

-0.88 (-2.30%)

SGEN Seagen
$153.20 /

-2.99 (-1.91%)

RIGL Rigel Pharmaceuticals
$4.27 /

-0.1 (-2.29%)

QURE uniQure
$34.46 /

-0.43 (-1.23%)

ORTX Orchard Therapeutics
$4.85 /

-0.19 (-3.77%)

MGTA Magenta Therapeutics
$11.38 /

+0.05 (+0.44%)

MEIP MEI Pharma
$3.10 /

-0.15 (-4.62%)

MBIO Mustang Bio
$3.57 /

-0.115 (-3.13%)

KROS Keros Therapeutics
$52.55 /

-0.455 (-0.86%)

JAZZ Jazz Pharmaceuticals
$183.42 /

-2.7 (-1.45%)

INCY Incyte
$82.69 /

+0.11 (+0.13%)

IMRA Imara
$8.26 /

-0.44 (-5.06%)

GBT Global Blood Therapeutics
$39.60 /

-0.65 (-1.61%)

FMTX Forma Therapeutics
$24.13 /

-0.09 (-0.37%)

EQ Equillium
$6.05 /

+0.05 (+0.83%)

EPZM Epizyme
$8.79 /

-0.025 (-0.28%)

CYAD Celyad
$5.44 /

+0.03 (+0.55%)

CRIS Curis
$7.61 /

-0.44 (-5.47%)

BGNE BeiGene
$332.97 /

-9.75 (-2.84%)

APTO Aptose Biosciences
$3.50 /

-0.21 (-5.66%)

APLS Apellis
$60.63 /

-4.27 (-6.58%)

ALXN Alexion
$181.90 /

+0.25 (+0.14%)

AGIO Agios Pharmaceuticals
$58.23 /

+0.04 (+0.07%)

APTO Aptose Biosciences
$3.50 /

-0.21 (-5.66%)

02/22/21 JonesTrading
Aptose Biosciences resumed with a Buy at JonesTrading
10/19/20 Cantor Fitzgerald
Aptose Biosciences initiated with an Overweight at Cantor Fitzgerald
09/22/20 Alliance Global Partners
Aptose Biosciences initiated with a Buy at Alliance Global Partners
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
MBIO Mustang Bio
$3.57 /

-0.115 (-3.13%)

05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/12/21 Cantor Fitzgerald
Mustang Bio EHA abstract data 'looks promising,' says Cantor Fitzgerald
12/23/20 B. Riley
Mustang Bio transferred with a Buy at B. Riley Securities
QURE uniQure
$34.46 /

-0.43 (-1.23%)

06/14/21 BTIG
uniQure initiated with a Buy at BTIG
05/20/21 UBS
uniQure initiated with a Neutral at UBS
05/19/21 H.C. Wainwright
uniQure price target raised to $90 from $80 at H.C. Wainwright
04/26/21 Chardan
Chardan sees 'stock momentum' for uniQure after clinical hold lift
RIGL Rigel Pharmaceuticals
$4.27 /

-0.1 (-2.29%)

06/11/21 BMO Capital
Rigel Pharmaceuticals coverage transferred at BMO Capital
05/12/21 Cantor Fitzgerald
Rigel rallying on Curis IRAK4 program data, says Cantor Fitzgerald
04/13/21 Piper Sandler
Rigel results in severe COVID-19 trial 'pretty dramatic,' says Piper Sandler
02/18/21 H.C. Wainwright
Rigel Pharmaceuticals price target raised to $11 from $8 at H.C. Wainwright
MGTA Magenta Therapeutics
$11.38 /

+0.05 (+0.44%)

06/14/21 BTIG
Magenta Therapeutics initiated with a Buy at BTIG
05/18/21 B. Riley
Magenta Therapeutics initiated with a Buy, $21 target at B. Riley
05/17/21 B. Riley
Magenta Therapeutics initiated with a Buy at B. Riley
05/13/21 Mizuho
Magenta Therapeutics price target raised to $17 from $16 at Mizuho
MEIP MEI Pharma
$3.10 /

-0.15 (-4.62%)

04/26/21 Wells Fargo
MEI Pharma likely to expand scope of voruciclib development, says Wells Fargo
10/12/20 Brookline
MEI Pharma initiated with a Buy at Brookline
09/22/20 Alliance Global Partners
MEI Pharma initiated with a Buy at Alliance Global Partners
07/06/20 Truist
MEI Pharma price target lowered to $12 from $16 at SunTrust
CRIS Curis
$7.61 /

-0.44 (-5.47%)

05/13/21 B. Riley
Curis price target raised to $22 from $19 at B. Riley
05/13/21 Cantor Fitzgerald
Curis price target raised to $24 from $15 at Cantor Fitzgerald
05/12/21 Cantor Fitzgerald
Initial look from Curis EHA updates 'very positive,' says Cantor Fitzgerald
XLRN Acceleron
$128.63 /

-2.39 (-1.82%)

06/11/21 H.C. Wainwright
Acceleron results for Phase 2 BEYOND study 'impressive,' says H.C. Wainwright
05/19/21 Piper Sandler
Piper remains bullish on Acceleron after Phase 2 PULSAR OLE, SPECTRA updates
04/26/21 Credit Suisse
Acceleron assumed with an Outperform at Credit Suisse
03/23/21
Fly Intel: Top five analyst downgrades
EPZM Epizyme
$8.79 /

-0.025 (-0.28%)

05/07/21 SVB Leerink
Epizyme upgraded to Outperform from Market Perform at SVB Leerink
04/23/21 Cowen
Epizyme transferred with Outperform at Cowen
03/30/21 Credit Suisse
Epizyme initiated with an Outperform at Credit Suisse
03/30/21 Credit Suisse
Epizyme initiated with an Outperform at Credit Suisse
INCY Incyte
$82.69 /

+0.11 (+0.13%)

02/10/21 SVB Leerink
Incyte downgraded to Market Perform from Outperform at SVB Leerink
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/04/21 Guggenheim
Incyte upgraded to Buy from Neutral at Guggenheim
ORTX Orchard Therapeutics
$4.85 /

-0.19 (-3.77%)

03/10/21 Stifel
Stifel says Bluebird update on AML provides 'some relief' to other LV players
03/02/21 JPMorgan
Orchard Therapeutics assumed with an Overweight at JPMorgan
03/01/21 Stifel
Orchard Therapeutics initiated with a Buy at Stifel
02/18/21 Goldman Sachs
Orchard selloff on Bluebird Bio news overdone, says Goldman Sachs
TGTX TG Therapeutics
$37.42 /

-0.88 (-2.30%)

04/20/21
Fly Intel: Top five analyst initiations
04/20/21 Goldman Sachs
TG Therapeutics initiated with a Neutral at Goldman Sachs
04/19/21 Cantor Fitzgerald
TG Therapeutics price target raised to $74 from $68 at Cantor Fitzgerald
04/19/21 H.C. Wainwright
TG Therapeutics price target raised to $89 from $79 at H.C. Wainwright
EQ Equillium
$6.05 /

+0.05 (+0.83%)

03/03/21
Fly Intel: Top five analyst initiations
03/03/21 JonesTrading
Equillium initiated with a Buy at JonesTrading
11/30/20 H.C. Wainwright
Equillium price target lowered to $12 from $22 at H.C. Wainwright
07/14/20 H.C. Wainwright
Equillium price target raised to $24 from $14 at H.C. Wainwright
JAZZ Jazz Pharmaceuticals
$183.42 /

-2.7 (-1.45%)

05/19/21
Fly Intel: Top five analyst initiations
05/19/21 JPMorgan
Jazz Pharmaceuticals resumed with an Overweight at JPMorgan
05/17/21 H.C. Wainwright
Jazz Pharmaceuticals price target raised to $212 from $207 at H.C. Wainwright
04/21/21 Cantor Fitzgerald
Jazz Pharmaceuticals price target raised to $198 from $185 at Cantor Fitzgerald
VRTX Vertex Pharmaceuticals
$188.94 /

-5.87 (-3.01%)

06/14/21 Truist
Vertex Pharmaceuticals price target raised to $331 from $305 at Truist
06/14/21 SVB Leerink
Vertex Pharmaceuticals price target lowered to $200 from $250 at SVB Leerink
06/14/21 Deutsche Bank
Grifols upgraded to Buy from Hold at Deutsche Bank
06/13/21 Piper Sandler
Vertex Pharmaceuticals price target lowered to $261 from $347 at Piper Sandler
SGEN Seagen
$153.20 /

-2.99 (-1.91%)

05/17/21 Evercore ISI
Seagen initiated with an In Line at Evercore ISI
04/30/21 Piper Sandler
Seagen price target lowered to $160 from $170 at Piper Sandler
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
03/30/21 Credit Suisse
Seagen initiated with a Neutral at Credit Suisse
IMRA Imara
$8.26 /

-0.44 (-5.06%)

03/08/21 SVB Leerink
Imara price target lowered to $42 from $59 at SVB Leerink
01/06/21 SVB Leerink
Imara selloff a potential buying opportunity, says SVB Leerink
08/17/20
Fly Intel: Top five analyst upgrades
08/17/20 Citi
Imara upgraded to Buy from Neutral at Citi
GBT Global Blood Therapeutics
$39.60 /

-0.65 (-1.61%)

05/07/21 Cantor Fitzgerald
Global Blood Therapeutics price target lowered to $110 from $120 at Cantor Fitzgerald
05/06/21 Piper Sandler
Global Blood price target lowered to $45 from $50 at Piper Sandler
04/14/21
Fly Intel: Top five analyst initiations
04/14/21 SVB Leerink
SVB Leerink bullish on Global Blood Therapeutics, initiates with an Outperform
BGNE BeiGene
$332.97 /

-9.75 (-2.84%)

06/14/21 SVB Leerink
BeiGene price target raised to $417 from $388 at SVB Leerink
03/16/21 HSBC
BeiGene price target raised to $385 from $296 at HSBC
03/08/21 China Renaissance
BeiGene initiated with a Buy at China Renaissance
03/04/21 Goldman Sachs
Five Prime acquisition 'a strategic positive' for Amgen, says Goldman Sachs
APLS Apellis
$60.63 /

-4.27 (-6.58%)

05/20/21 UBS
Apellis initiated with a Buy at UBS
05/18/21 BMO Capital
Apellis price target raised to $68 from $64 at BMO Capital
05/17/21 Oppenheimer
Apellis price target raised to $67 from $64 at Oppenheimer
05/17/21 Raymond James
Apellis price target raised to $115 from $104 at Raymond James
AGIO Agios Pharmaceuticals
$58.23 /

+0.04 (+0.07%)

06/10/21 H.C. Wainwright
Agios Pharmaceuticals initiated with a Buy at H.C. Wainwright
04/30/21 Goldman Sachs
Agios Pharmaceuticals reinstated with a Neutral at Goldman Sachs
04/30/21 Barclays
Agios Pharmaceuticals price target raised to $70 from $65 at Barclays
03/30/21 Piper Sandler
Agios should rally on Forma Therapeutics data, says Piper Sandler
FMTX Forma Therapeutics
$24.13 /

-0.09 (-0.37%)

03/31/21 H.C. Wainwright
Forma Therapeutics price target raised to $55 from $53 at H.C. Wainwright
02/17/21
Fly Intel: Top five analyst initiations
02/17/21 Oppenheimer
Forma Therapeutics initiated with an Outperform at Oppenheimer
KROS Keros Therapeutics
$52.55 /

-0.455 (-0.86%)

12/08/20 SVB Leerink
Keros Therapeutics price target raised to $80 from $42 at SVB Leerink
12/08/20 H.C. Wainwright
Keros Therapeutics price target raised to $100 from $50 at H.C. Wainwright
12/08/20 Piper Sandler
Keros Therapeutics price target raised to $95 from $75 at Piper Sandler
11/18/20 Piper Sandler
Keros Therapeutics price target raised to $75 from $55 at Piper Sandler
CYAD Celyad
$5.44 /

+0.03 (+0.55%)

03/25/21 JonesTrading
Celyad downgraded to Hold from Buy at JonesTrading
12/08/20 H.C. Wainwright
Celyad price target lowered to $18 from $22 at H.C. Wainwright
ALXN Alexion
$181.90 /

+0.25 (+0.14%)

05/05/21
Fly Intel: Top five analyst upgrades
05/05/21 Oppenheimer
Alexion upgraded to Outperform from Perform at Oppenheimer
05/03/21 SVB Leerink
Alexion price target raised to $173 from $156 at SVB Leerink
04/30/21 Wedbush
Alexion's Q1 report 'uneventful' after FTC grants deal clearance, says Wedbush
XLRN Acceleron
$128.63 /

-2.39 (-1.82%)

VRTX Vertex Pharmaceuticals
$188.94 /

-5.87 (-3.01%)

TGTX TG Therapeutics
$37.42 /

-0.88 (-2.30%)

SGEN Seagen
$153.20 /

-2.99 (-1.91%)

RIGL Rigel Pharmaceuticals
$4.27 /

-0.1 (-2.29%)

QURE uniQure
$34.46 /

-0.43 (-1.23%)

ORTX Orchard Therapeutics
$4.85 /

-0.19 (-3.77%)

MGTA Magenta Therapeutics
$11.38 /

+0.05 (+0.44%)

MEIP MEI Pharma
$3.10 /

-0.15 (-4.62%)

MBIO Mustang Bio
$3.57 /

-0.115 (-3.13%)

KROS Keros Therapeutics
$52.55 /

-0.455 (-0.86%)

JAZZ Jazz Pharmaceuticals
$183.42 /

-2.7 (-1.45%)

INCY Incyte
$82.69 /

+0.11 (+0.13%)

IMRA Imara
$8.26 /

-0.44 (-5.06%)

GBT Global Blood Therapeutics
$39.60 /

-0.65 (-1.61%)

FMTX Forma Therapeutics
$24.13 /

-0.09 (-0.37%)

EQ Equillium
$6.05 /

+0.05 (+0.83%)

EPZM Epizyme
$8.79 /

-0.025 (-0.28%)

CRIS Curis
$7.61 /

-0.44 (-5.47%)

BGNE BeiGene
$332.97 /

-9.75 (-2.84%)

APTO Aptose Biosciences
$3.50 /

-0.21 (-5.66%)

APLS Apellis
$60.63 /

-4.27 (-6.58%)

ALXN Alexion
$181.90 /

+0.25 (+0.14%)

AGIO Agios Pharmaceuticals
$58.23 /

+0.04 (+0.07%)

  • 15
    Dec
  • 09
    Dec
  • 11
    Dec
  • 02
    Dec
  • 13
    Nov
  • 14
    Aug
  • 16
    Jul
  • 01
    Jul
  • 25
    Jun
  • 19
    Jun
VRTX Vertex Pharmaceuticals
$188.94 /

-5.87 (-3.01%)

RIGL Rigel Pharmaceuticals
$4.27 /

-0.1 (-2.29%)

ORTX Orchard Therapeutics
$4.85 /

-0.19 (-3.77%)

JAZZ Jazz Pharmaceuticals
$183.42 /

-2.7 (-1.45%)

INCY Incyte
$82.69 /

+0.11 (+0.13%)

EPZM Epizyme
$8.79 /

-0.025 (-0.28%)

VRTX Vertex Pharmaceuticals
$188.94 /

-5.87 (-3.01%)

TGTX TG Therapeutics
$37.42 /

-0.88 (-2.30%)

SGEN Seagen
$153.20 /

-2.99 (-1.91%)

QURE uniQure
$34.46 /

-0.43 (-1.23%)

MBIO Mustang Bio
$3.57 /

-0.115 (-3.13%)

JAZZ Jazz Pharmaceuticals
$183.42 /

-2.7 (-1.45%)

INCY Incyte
$82.69 /

+0.11 (+0.13%)

IMRA Imara
$8.26 /

-0.44 (-5.06%)

GBT Global Blood Therapeutics
$39.60 /

-0.65 (-1.61%)

EQ Equillium
$6.05 /

+0.05 (+0.83%)

CRIS Curis
$7.61 /

-0.44 (-5.47%)

APTO Aptose Biosciences
$3.50 /

-0.21 (-5.66%)

APLS Apellis
$60.63 /

-4.27 (-6.58%)

ALXN Alexion
$181.90 /

+0.25 (+0.14%)

VRTX Vertex Pharmaceuticals
$188.94 /

-5.87 (-3.01%)

INCY Incyte
$82.69 /

+0.11 (+0.13%)

FMTX Forma Therapeutics
$24.13 /

-0.09 (-0.37%)

EQ Equillium
$6.05 /

+0.05 (+0.83%)

CRIS Curis
$7.61 /

-0.44 (-5.47%)

APLS Apellis
$60.63 /

-4.27 (-6.58%)

ALXN Alexion
$181.90 /

+0.25 (+0.14%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.